nach oben

Cancer Immunology, Immunotherapy

Erschienen in:

10.07.2020 | Review

Augmenting engineered T-cell strategies in solid cancers through epigenetic priming

verfasst von: Aaraby Y. Nielsen, Maria Ormhøj, Sofie Traynor, Morten F. Gjerstorff

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 11/2020

Einloggen, um Zugang zu erhalten

Abstract

T-cell receptor (TCR)- and chimeric antigen receptor (CAR)-based adoptive cell transfer (ACT) has shown promising results in hematological malignancies, but remains immature in solid cancers. The challenges associated with identification of tumor-specific targets, the heterogenic antigen expression, limited T-cell trafficking to tumor sites and the hostile tumor microenvironment (TME), are all factors contributing to the limited efficacy of ACT therapies against solid tumors. Epigenetic priming of tumor cells and the microenvironment may be a way of overcoming these obstacles and improving the clinical efficacy of adoptive T-cell therapies in the future. Here, we review the current literature and suggest combining epigenetic modulators and ACT strategies as a way of augmenting the efficacy of TCR- and CAR-engineered T cells against solid tumors.

Zheng PP, Kros JM, Li J (2018) Approved CAR T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts. Drug Discov Today 23(6):1175–1182PubMed

Matsuda T, Leisegang M, Park JH, Ren L, Kato T, Ikeda Y et al (2018) Induction of neoantigen-specific cytotoxic T cells and construction of T-cell receptor-engineered T cells for ovarian cancer. Clin Cancer Res 24(21):5357–5367PubMed

Guedan S, Calderon H, Posey AD Jr, Maus MV (2019) Engineering and Design of Chimeric Antigen Receptors. Mol Ther Methods Clin Dev 12:145–156PubMed

Carter CA, Oronsky BT, Roswarski J, Oronsky AL, Oronsky N, Scicinski J et al (2017) No patient left behind: the promise of immune priming with epigenetic agents. Oncoimmunology 6(10):e1315486PubMedPubMedCentral

Jones PA, Ohtani H, Chakravarthy A, De Carvalho DD (2019) Epigenetic therapy in immune-oncology. Nat Rev Cancer 19(3):151–161PubMed

Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z et al (2013) Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother 36(2):133–151PubMedPubMedCentral

Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA (2010) Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 18(4):843–851PubMedPubMedCentral

Liu S, Matsuzaki J, Wei L, Tsuji T, Battaglia S, Hu Q et al (2019) Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer. J Immunother Cancer 7(1):156PubMedPubMedCentral

O'Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD et al (2017) A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med 9(399):eaaa0984. https://doi.org/10.1126/scitranslmed.aaa0984CrossRefPubMedPubMedCentral

10.

Gjerstorff MF, Andersen MH, Ditzel HJ (2015) Oncogenic cancer/testis antigens: prime candidates for immunotherapy. Oncotarget 6(18):15772–15787PubMedPubMedCentral

11.

Scanlan MJ, Simpson AJ, Old LJ (2004) The cancer/testis genes: review, standardization, and commentary. Cancer Immun 4:1PubMed

12.

Maus MV, Plotkin J, Jakka G, Stewart-Jones G, Riviere I, Merghoub T et al (2016) An MHC-restricted antibody-based chimeric antigen receptor requires TCR-like affinity to maintain antigen specificity. Mol Ther Oncolytics 3:1–9PubMed

13.

Sotillo E, Barrett DM, Black KL, Bagashev A, Oldridge D, Wu G et al (2015) Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov 5(12):1282–1295PubMedPubMedCentral

14.

Rapoport AP, Stadtmauer EA, Binder-Scholl GK, Goloubeva O, Vogl DT, Lacey SF et al (2015) NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med 21(8):914–921PubMedPubMedCentral

15.

Hegde M, Mukherjee M, Grada Z, Pignata A, Landi D, Navai SA et al (2016) Tandem CAR T cells targeting HER2 and IL13Ralpha2 mitigate tumor antigen escape. J Clin Invest 126(8):3036–3052PubMedPubMedCentral

16.

Massa C, Seliger B (2019) The tumor microenvironment: thousand obstacles for effector T cells. Cell Immunol 343:103730PubMed

17.

John LB, Devaud C, Duong CP, Yong CS, Beavis PA, Haynes NM et al (2013) Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res 19(20):5636–5646PubMed

18.

Kloss CC, Lee J, Zhang A, Chen F, Melenhorst JJ, Lacey SF et al (2018) Dominant-negative TGF-beta receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication. Mol Ther 26(7):1855–1866PubMedPubMedCentral

19.

Feinberg AP, Ohlsson R, Henikoff S (2006) The epigenetic progenitor origin of human cancer. Nat Rev Genet 7(1):21–33PubMed

20.

Chatterjee A, Rodger EJ, Eccles MR (2018) Epigenetic drivers of tumourigenesis and cancer metastasis. Semin Cancer Biol 51:149–159PubMed

21.

Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3(6):415–428PubMed

22.

Jones PA, Baylin SB (2007) The epigenomics of cancer. Cell 128(4):683–692PubMedPubMedCentral

23.

Rodriguez-Paredes M, Esteller M (2011) Cancer epigenetics reaches mainstream oncology. Nat Med 17(3):330–339PubMed

24.

Li Y, Seto E (2016) HDACs and HDAC inhibitors in cancer development and therapy. Cold Spring Harb Perspect Med 6(10):a026831. https://doi.org/10.1101/cshperspect.a026831CrossRefPubMedPubMedCentral

25.

Cheng Y, He C, Wang M, Ma X, Mo F, Yang S et al (2019) Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials. Signal Transduct Target Ther 4:62PubMedPubMedCentral

26.

Sigalotti L, Fratta E, Coral S, Tanzarella S, Danielli R, Colizzi F et al (2004) Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2'-deoxycytidine. Cancer Res 64(24):9167–9171PubMed

27.

Weber J, Salgaller M, Samid D, Johnson B, Herlyn M, Lassam N et al (1994) Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2'-deoxycytidine. Cancer Res 54(7):1766–1771PubMed

28.

Fratta E, Coral S, Covre A, Parisi G, Colizzi F, Danielli R et al (2011) The biology of cancer testis antigens: putative function, regulation and therapeutic potential. Mol Oncol 5(2):164–182PubMedPubMedCentral

29.

Srivastava P, Paluch BE, Matsuzaki J, James SR, Collamat-Lai G, Taverna P et al (2015) Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts. Epigenetics 10(3):237–246PubMedPubMedCentral

30.

Heninger E, Krueger TE, Thiede SM, Sperger JM, Byers BL, Kircher MR et al (2016) Inducible expression of cancer-testis antigens in human prostate cancer. Oncotarget 7(51):84359–84374PubMedPubMedCentral

31.

Karpf AR, Lasek AW, Ririe TO, Hanks AN, Grossman D, Jones DA (2004) Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine. Mol Pharmacol 65(1):18–27PubMed

32.

Wolff F, Leisch M, Greil R, Risch A, Pleyer L (2017) The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulation. Cell Commun Signal 15(1):13PubMedPubMedCentral

33.

Shahbazian MD, Grunstein M (2007) Functions of site-specific histone acetylation and deacetylation. Annu Rev Biochem 76:75–100PubMed

34.

Wischnewski F, Pantel K, Schwarzenbach H (2006) Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells. Mol Cancer Res 4(5):339–349PubMed

35.

Link PA, Gangisetty O, James SR, Woloszynska-Read A, Tachibana M, Shinkai Y et al (2009) Distinct roles for histone methyltransferases G9a and GLP in cancer germ-line antigen gene regulation in human cancer cells and murine embryonic stem cells. Mol Cancer Res 7(6):851–862PubMedPubMedCentral

36.

Sun F, Chan E, Wu Z, Yang X, Marquez VE, Yu Q (2009) Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells. Mol Cancer Ther 8(12):3191–3202PubMedPubMedCentral

37.

Zhang M, Liang JQ, Zheng S (2019) Expressional activation and functional roles of human endogenous retroviruses in cancers. Rev Med Virol 29(2):e2025PubMedPubMedCentral

38.

Alcazer V, Bonaventura P, Depil S (2020) Human endogenous retroviruses (HERVs): shaping the innate immune response in cancers. Cancers (Basel) 12(3):610. https://doi.org/10.3390/cancers12030610CrossRef

39.

Daskalakis M, Brocks D, Sheng YH, Islam MS, Ressnerova A, Assenov Y et al (2018) Reactivation of endogenous retroviral elements via treatment with DNMT- and HDAC-inhibitors. Cell Cycle 17(7):811–822PubMedPubMedCentral

40.

Krishnamurthy J, Rabinovich BA, Mi T, Switzer KC, Olivares S, Maiti SN et al (2015) Genetic engineering of T cells to target HERV-K, an ancient retrovirus on melanoma. Clin Cancer Res 21(14):3241–3251PubMedPubMedCentral

41.

Garrido F, Cabrera T, Aptsiauri N (2010) “Hard” and “soft” lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy. Int J Cancer 127(2):249–256PubMed

42.

Garrido F (2019) MHC/HLA class I loss in cancer cells. Adv Exp Med Biol 1151:15–78PubMed

43.

Campoli M, Ferrone S (2008) HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene 27(45):5869–5885PubMedPubMedCentral

44.

Luo N, Nixon MJ, Gonzalez-Ericsson PI, Sanchez V, Opalenik SR, Li H et al (2018) DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer. Nat Commun 9(1):248PubMedPubMedCentral

45.

Chiappinelli KB, Strissel PL, Desrichard A, Li H, Henke C, Akman B et al (2015) Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell 162(5):974–986PubMedPubMedCentral

46.

Roulois D, Loo Yau H, Singhania R, Wang Y, Danesh A, Shen SY et al (2015) DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell 162(5):961–973PubMedPubMedCentral

47.

Li H, Chiappinelli KB, Guzzetta AA, Easwaran H, Yen RW, Vatapalli R et al (2014) Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget 5(3):587–598PubMedPubMedCentral

48.

Stone ML, Chiappinelli KB, Li H, Murphy LM, Travers ME, Topper MJ et al (2017) Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden. Proc Natl Acad Sci USA 114(51):E10981–E10990PubMed

49.

Peng D, Kryczek I, Nagarsheth N, Zhao L, Wei S, Wang W et al (2015) Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature 527(7577):249–253PubMedPubMedCentral

50.

Kim K, Skora AD, Li Z, Liu Q, Tam AJ, Blosser RL et al (2014) Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc Natl Acad Sci USA 111(32):11774–11779PubMed

51.

Zhou J, Yao Y, Shen Q, Li G, Hu L, Zhang X (2017) Demethylating agent decitabine disrupts tumor-induced immune tolerance by depleting myeloid-derived suppressor cells. J Cancer Res Clin Oncol 143(8):1371–1380PubMed

52.

Terracina KP, Graham LJ, Payne KK, Manjili MH, Baek A, Damle SR et al (2016) DNA methyltransferase inhibition increases efficacy of adoptive cellular immunotherapy of murine breast cancer. Cancer Immunol Immunother 65(9):1061–1073PubMedPubMedCentral

53.

Lal G, Zhang N, van der Touw W, Ding Y, Ju W, Bottinger EP et al (2009) Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation. J Immunol 182(1):259–273PubMedPubMedCentral

54.

Costantini B, Kordasti SY, Kulasekararaj AG, Jiang J, Seidl T, Abellan PP et al (2013) The effects of 5-azacytidine on the function and number of regulatory T cells and T-effectors in myelodysplastic syndrome. Haematologica 98(8):1196–1205PubMedPubMedCentral

55.

Wang D, Quiros J, Mahuron K, Pai CC, Ranzani V, Young A et al (2018) Targeting EZH2 reprograms intratumoral regulatory T cells to Enhance cancer immunity. Cell Rep 23(11):3262–3274PubMedPubMedCentral

56.

Adeegbe DO, Liu Y, Lizotte PH, Kamihara Y, Aref AR, Almonte C et al (2017) Synergistic immunostimulatory effects and therapeutic benefit of combined histone deacetylase and bromodomain inhibition in non-small cell lung cancer. Cancer Discov 7(8):852–867PubMedPubMedCentral

57.

Stubig T, Badbaran A, Luetkens T, Hildebrandt Y, Atanackovic D, Binder TM et al (2014) 5-azacytidine promotes an inhibitory T-cell phenotype and impairs immune mediated antileukemic activity. Mediators Inflamm 2014:418292PubMedPubMedCentral

58.

Ghoneim HE, Fan Y, Moustaki A, Abdelsamed HA, Dash P, Dogra P et al (2017) De novo epigenetic programs inhibit PD-1 blockade-mediated T cell rejuvenation. Cell 170(1):142–57e19PubMedPubMedCentral

59.

Guo ZS, Hong JA, Irvine KR, Chen GA, Spiess PJ, Liu Y et al (2006) De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model. Cancer Res 66(2):1105–1113PubMedPubMedCentral

60.

Kunert A, van Brakel M, van Steenbergen-Langeveld S, da Silva M, Coulie PG, Lamers C et al (2016) MAGE-C2-specific TCRs combined with epigenetic drug-enhanced antigenicity yield robust and tumor-selective T cell responses. J Immunol 197(6):2541–2552PubMed

61.

Chou J, Voong LN, Mortales CL, Towlerton AM, Pollack SM, Chen X et al (2012) Epigenetic modulation to enable antigen-specific T-cell therapy of colorectal cancer. J Immunother 35(2):131–141PubMedPubMedCentral

62.

Natsume A, Wakabayashi T, Tsujimura K, Shimato S, Ito M, Kuzushima K et al (2008) The DNA demethylating agent 5-aza-2'-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma. Int J Cancer 122(11):2542–2553PubMed

63.

Yan M, Himoudi N, Basu BP, Wallace R, Poon E, Adams S et al (2011) Increased PRAME antigen-specific killing of malignant cell lines by low avidity CTL clones, following treatment with 5-Aza-2'-Deoxycytidine. Cancer Immunol Immunother 60(9):1243–1255PubMed

64.

Vo DD, Prins RM, Begley JL, Donahue TR, Morris LF, Bruhn KW et al (2009) Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824. Cancer Res 69(22):8693–8699PubMedPubMedCentral

65.

Kailayangiri S, Altvater B, Lesch S, Balbach S, Gottlich C, Kuhnemundt J et al (2019) EZH2 inhibition in Ewing sarcoma upregulates GD2 expression for targeting with gene-modified T cells. Mol Ther 27(5):933–946PubMedPubMedCentral

Titel: Augmenting engineered T-cell strategies in solid cancers through epigenetic priming
verfasst von: Aaraby Y. Nielsen
Maria Ormhøj
Sofie Traynor
Morten F. Gjerstorff
Publikationsdatum: 10.07.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 11/2020
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-020-02661-1

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Augmenting engineered T-cell strategies in solid cancers through epigenetic priming

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2020

Differences in PD-1 expression on CD8+ T-cells in chronic myeloid leukemia patients according to disease phase and TKI medication

Exploratory open-label clinical study to determine the S-588410 cancer peptide vaccine-induced tumor-infiltrating lymphocytes and changes in the tumor microenvironment in esophageal cancer patients

Immune resilience in response to cancer therapy

Micro-environmental cross-talk in an organotypic human melanoma-in-skin model directs M2-like monocyte differentiation via IL-10

Metabolomic profiling of tumor-infiltrating macrophages during tumor growth

Expression profiles and function of IL6 in polymorphonuclear myeloid-derived suppressor cells

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie